Metavas MR

Trimetazidine Dihydrochloride
35 mg Tablet
Description:

Metavas MR (Trimetazidine Dihydrochloride) is the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients. Metavas MR (Trimetazidine) inhibits fatty acid pathway by inhibiting 3-keto acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose pathway is more efficient in producing energy, the same oxygen produces more energy and makes the heat more active. Moreover, the aerobic oxidation of glucose stops production of lactic acid, which prevents angina pectoris.


  • Composition

    Each modified release tablet contains Trimetazidine Dihydrochloride BP 35 mg.
  • Indication

    Metavas MR (Trimetazidine Dihydrochloride) is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies.
  • Dosage & Administration

    The recommended dose of Trimetazidine is 35 mg twice daily during meals. The benefit of the treatment should be assessed after three months and Trimetazidine should be discontinued if there is no treatment response.
  • Contraindication

    Trimetazidine is contraindicated in patients who have hypersensitivity to the active substance or to any of the excipients. It is also is contraindicated in patients with Parkinson disease, parkinsonian symptoms, tremors, restlessleg movement disorders, severe renal impairment.
  • Precaution

    Trimetazidine is not a curative treatment for angina attacks, nor an initial treatment for unstable angina pectoris. It is not a treatment for myocardial infarction.
  • Side Effects

    Trimetazidine is safe and well tolerated. The Common side effects associated with Trimetazidine are dizziness, headache, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria and asthenia
  • Drug Interaction

    No drug interactions so far have been reported. In particular, no interactions have been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents or digitalis preparation.
  • Overdose

  • Pregnancy & Lactation

    There are no data from the use of Trimetazidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Trimetazidine during pregnancy. It is unknown whether Trimetazidine is excreted in human milk. A risk to the newborns/infants cannot be excluded. Trimetazidine should not be used during breast-feeding.
  • Storage Condition

    Keep in a dry place away from light and heat. Keep out of the reach of children.
  • How Supplied

    Each box contains 30 tablets in alu-alu blister pack